CanAg

	CanAg Cantuzumab is a monoclonal antibody designed for the treatment of cancers. Also known as huC242 it binds the CanAg antigen. It is typically linked to one of several cytotoxic agents, yielding antibody-drug conjugates : * Cantuzumab mertansine * Cantuzumab ravtansine huC242 targets CanAg "HuC242 binds to the extracellular domain of the tumor-associated carbohydrate antigen known as CanAg (a novel glycoform of MUC1 Mucin short variant S1, also called polymorphic epithelial mucin (PEM) or epithelial membrane antigen (EMA), is a mucin encoded by the ''MUC1'' gene in humans. Mucin short variant S1 is a glycoprotein with extensive O-linked glycosylation of its ...). CanAg is strongly expressed in most pancreatic, biliary, and colorectal cancers. It is also expressed in a substantial proportion of gastric cancers (55%), uterine cancers (45%), non-small cell lung cancers (40%), and bladder cancers (40%)." References Monoclonal antibodies {{monoclonal-antibody-stub ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu]
	Cantuzumab Mertansine Cantuzumab mertansine (SB-408075; huC242-DM1) is an antibody-drug conjugate investigated to treat colorectal cancer and other types of cancer. It is a humanized monoclonal antibody, cantuzumab (huC242) linked to a cytotoxic agent, mertansine (DM1). It was developed by ImmunoGen. Mechanism After the huC242 mab binds to the external domain of CanAg, the cantuzumab mertansine-CanAg complex is internalized, and the DM1 molecules are released intracellularly by cleavage of the DM1-huC242 disulfide bond In chemistry, a disulfide (or disulphide in British English) is a compound containing a functional group or the anion. The linkage is also called an SS-bond or sometimes a disulfide bridge and usually derived from two thiol groups. In inor ...s. Clinical trials Three phase I clinical studies had reported results by 2003. By 2005, clinical development had been suspended. See also * Cantuzumab ravtansine References Antibody-drug conjugates Monoclonal antibodies f ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu]
	MUC1 Mucin short variant S1, also called polymorphic epithelial mucin (PEM) or epithelial membrane antigen (EMA), is a mucin encoded by the ''MUC1'' gene in humans. Mucin short variant S1 is a glycoprotein with extensive O-linked glycosylation of its extracellular domain. Mucins line the apical surface of epithelial cells in the lungs, stomach, intestines, eyes and several other organs. Mucins protect the body from infection by pathogen binding to oligosaccharides in the extracellular domain, preventing the pathogen from reaching the cell surface. Overexpression of MUC1 is often associated with colon, breast, ovarian, lung and pancreatic cancers. Joyce Taylor-Papadimitriou identified and characterised the antigen during her work with breast and ovarian tumors. Structure MUC1 is a member of the mucin family and encodes a membrane bound, glycosylated phosphoprotein. MUC1 has a core protein mass of 120-225 kDa which increases to 250-500 kDa with glycosylation. It extends 200-500&n ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu]
	Monoclonal Antibody A monoclonal antibody (mAb, more rarely called moAb) is an antibody produced from a cell lineage made by cloning a unique white blood cell. All subsequent antibodies derived this way trace back to a unique parent cell. Monoclonal antibodies are identical and can thus have monovalent affinity, binding only to a particular epitope (the part of an antigen that is recognized by the antibody). In contrast, polyclonal antibodies are mixtures of antibodies derived from multiple plasma cell lineages which each bind to their particular target epitope. Artificial antibodies known as bispecific monoclonal antibodies can also be engineered which include two different antigen binding sites ( FABs) on the same antibody. It is possible to produce monoclonal antibodies that specifically bind to almost any suitable substance; they can then serve to detect or purify it. This capability has become an investigative tool in biochemistry, molecular biology, and medicine. Monoclonal antibod ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu]
	Cantuzumab Ravtansine Cantuzumab ravtansine (huC242-SPDB-DM4) is an antibody-drug conjugate designed for the treatment of cancers. The humanized monoclonal antibody ''cantuzumab'' (huC242) is linked to a cytotoxic agent, ravtansine (DM4). It uses a more hindered disulfide linkage than cantuzumab mertansine. See also * Cantuzumab mertansine Cantuzumab mertansine (SB-408075; huC242-DM1) is an antibody-drug conjugate investigated to treat colorectal cancer and other types of cancer. It is a humanized monoclonal antibody, cantuzumab (huC242) linked to a cytotoxic agent, mertansine ( ... * ImmunoGen Inc, developer of DM4 based drugs References Immunology Monoclonal antibodies Antibody-drug conjugates {{monoclonal-antibody-stub ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu]